Advances in pulmonary drug delivery

Inhaled Proteins and Peptides MECHANISMS OF ABSORPTION AND CLEARANCE Immunogenicity Nonclinical Development Considerations EXAMPLES OF DEVELOPMENT CANDIDATES Inhaled rhDNase (Pulmozyme)Inhaled Insulin Inhaled Human Growth Hormone PTH1-34 Cyclosporine Alpha-1 Antitrypsin Inhaled Vaccines Anti-lgE Inhaled Gene Therapy Formulation Approaches FUTURE DIRECTIONS SUMMARY REFERENCES Inhaled Insulin. More Compelling than Ever UNMET NEED Current Guidelines INSULIN TREATMENT NOW RECOMMENDED EARLIER IN THE TREATMENT REGIME The First Generation Clinical Efficacy of Inhaled Insulin Reliability of Dosing Clinical Safety of Inhaled Insulin Pulmonary Safety SUMMARY REFERENCES Inhaled Therapeutic siRNA for the Treatment of Respiratory Diseases DELIVERY OF THERAPEUTIC siRNA TO THE LUNG BARRIERS TO siRNA DELIVERY TO THE LUNG NONVIRAL FORMULATIONS FOR PULMONARY siRNA DELIVERY Polymer-Based siRNA Delivery Systems Polyethylenimine Chitosan Poly (D,L-Lactide-co-Glycolide)Other Polymers Lipid-Based Delivery Systems for siRNA Peptides RNAi-BASED THERAPY FOR THE TREATMENT OF LUNG CANCER FUTURE PERSPECTIVE SUMMARY REFERENCES New Molecules to Treat Asthma and COPD ASTHMA COPD NEW MOLECULES TO TREAT ASTHMA AND COPD Chemokine and Cytokine Inhibitors Antiproteases Antioxidants PDE Inhibitors PI3K Inhibitors p38 Mitogen-Activated Protein Kinase Inhibitors Nuclear Factor Kappa-B Inhibitors Antimicrobials Antiageing Molecules CONCLUSION REFERENCES Inhaled Anticancer Agents DELIVERY OF INHALED ANTICANCER AGENTS Aerosol Deposition Targeting Airway Deposition of Drugs Formulations Solutions Dry Powders Liposomes Microparticles Nanoparticles Swellable Hydrogels Micelles Aerosol Delivery Devices INHALED ANTICANCER AGENTS Immunologics/Cytokines Chemotherapy Pharmacokinetics Preclinical Efficacy Inhaled Chemotherapeutic Agents Nucleoside Analogs Doxorubicin Liposomal 9-Nitrocamptothecin Platinum Agents Gene Therapy Antisense Therapy Bacteria CLINICAL USE OF INHALED ANTICANCER AGENTS Immunologics/Cytokines Chemotherapy Gene Therapy ADVERSE EFFECTS LIMITATIONS OF INHALED ANTICANCER AGENTS Environmental Contamination Unanswered Questions SUMMARY REFERENCES Inhaled Countermeasures for Respiratory Tract Viruses AEROSOL BIOLOGY SMALL ANIMAL MODELS AND AEROSOL TRANSMISSION RESPIRATORY VIRUS INFECTION COUNTERMEASURES FOR RESPIRATORY TRACT INFECTIONS INFLUENZA VIRUS, A PROTOTYPICAL RESPIRATORY TRACT VIRUS CONTROLLING INFLUENZA VIRUS DISEASE BURDEN Multiple formulations. BRIEF HISTORY OF INFLUENZA VACCINES LIVE-ATTENUATED INFLUENZA VACCINES PULMONARY DELIVERY PULMONARY DRUG DELIVERY AEROSOL INHALERS SAFETY OF AEROSOL VACCINES BENEFITS AND DRAWBACKS OF INHALED AGENTS CONSIDERATIONS SUMMARY REFERENCES Pulmonary Delivery of Antibiotics for Respiratory Infections NEBULIZATION DPI DPI Devices Powder Production and Particle Engineering ADVERSE EFFECTS AND PATIENT COMPLIANCE ADVANCED FORMULATIONS FOR PULMONARY DELIVERY OF ANTIMICROBIALS Liposomal Formulation Nanoparticles Inhaled Bacteriophage CONCLUSIONS REFERENCES Inhaled Liposomes PULMONARY RATIONALE AND HISTORY CHALLENGES IN DEVELOPING PHARMACEUTICAL LIPOSOME FORMULATIONS Analytical Challenges Manufacturing Challenges CONSIDERATIONS FOR INHALED PRODUCTS BIOCOMPATIBILITY AND FATE OF LIPOSOMES IN THE LUNG TREATMENT OF LUNG INFECTIONS WITH INHALED LIPOSOMAL ANTIBIOTICS Liposomal Ciprofloxacin Liposomal Amikacin (ARIKAYCE® Formerly ARIKACE)SUMMARY REFERENCES Inhaled Traditional Chinese Medicine for Respiratory Diseases INHALATION DELIVERY OF TCM Nebulized SHL Nebulized Yuxingcao Nebulized Qingkailing Nebulized Tanreqing Nebulized Andrographolides Other Nebulized TCMs INHALED TCM VIA MDI OR DPI RATIONALE FOR TCM INHALATION THERAPY SUMMARY REFERENCES Bronchoprovocation Tests for the Evaluation of Drug Efficacy in Asthma INDIRECT VERSUS DIRECT AIRWAY CHALLENGES DIRECT AIRWAY CHALLENGES Methacholine and Histamine Challenges Target Population Contraindications Safety Considerations Outcomes and Interpretation of Results INDIRECT AIRWAY CHALLENGES Mannitol Inhalation Challenge Target Population Safety Considerations Outcomes and Interpretation of Results Adenosine Monophosphate Inhalation Challenge Target Population Safety Considerations Outcomes and Interpretation of Results Target Population Safety Considerations Outcomes and Interpretation of Results CONCLUSION SUMMARY REFERENCES